Protean Presents Project DelPHI at AMP 22

DelPHI: Delivering Precision Health Insights for timely diagnosis and treatments, using Protean MAPS™ and Navify® Digital Tools

Roy Khalife, So Hyeon Park, Tara Love, Amin Gholami, Alexandra Markus, Helle Sorensen, and Anthony Magliocco will be presenting two case studies this year at AMP 22, on the use of DelPHI, Protean MAPS, and Navify Digital Tools for the timely diagnosis and/or treatment of cancer.

---

DelPHI for the Timely Diagnosis & Treatment of Epitheliod Sarcoma

Epithelioid sarcoma (ES) is a rare and commonly misdiagnosed soft-tissue tumor. This rarity poses significant challenges for diagnosis and understanding disease pathology.

Here we utilized a unique, systematic approach that combines molecular testing with digital decision support tools to diagnose a child’s ES and identify viable therapy options.

Click to view full poster (will be available November 5th)

DelPHI for the Treatment of Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is the most common of the rare soft tissue sarcomas that typically affect the head, neck or genitourinary tract and have a 5 year survival rate of under 30%.

Here we present a case that underwent pathology review and comprehensive genomic analysis powered by digital decision support tools, to provide the patient with targeted therapeutic options.

Click to view full poster (will be available November 5th)

---

For further information, please contact:

Anthony Magliocco MD
CEO & President of Protean BioDiagnostics

Email: info@proteanbiodx.com
Phone: 1 (813) 817 2042

---

About Protean BioDiagnostics

Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support.

We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.

---